First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

C. W. Menke; Carlos Gomez-Roca; Carla van Herpen; Andrew L. Coveler; Devalingam Mahalingam; Henk M. W. Verheul; Winette T. A. van der Graaf; Randolph Christen; Dominik Ruettinger; Stefan Weigand; Michael A. Cannarile; Florian Heil; Michael Brewster; Antje-Christine Walz; Tapan K. Nayak; Ernesto Guarin; Valerie Meresse; Christophe Le Tourneau

doi:10.18632/oncotarget.11098

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

C. W. Menke, Carlos Gomez-Roca, Carla van Herpen, Andrew L. Coveler, Devalingam Mahalingam, Henk M. W. Verheul, Winette T. A. van der Graaf, Randolph Christen, Dominik Ruettinger, Stefan Weigand, Michael A. Cannarile, Florian Heil, Michael Brewster, Antje-Christine Walz, Tapan K. Nayak, Ernesto Guarin, Valerie Meresse, Christophe Le Tourneau

Medical oncology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	80046-80058
Journal	Oncotarget
Volume	7
Issue number	48
DOIs	https://doi.org/10.18632/oncotarget.11098
Publication status	Published - 29 Nov 2016

Access to Document

10.18632/oncotarget.11098

Cite this

Menke, C. W., Gomez-Roca, C., van Herpen, C., Coveler, A. L., Mahalingam, D., Verheul, H. M. W., van der Graaf, W. T. A., Christen, R., Ruettinger, D., Weigand, S., Cannarile, M. A., Heil, F., Brewster, M., Walz, A-C., Nayak, T. K., Guarin, E., Meresse, V., & Le Tourneau, C. (2016). First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors. Oncotarget, 7(48), 80046-80058. https://doi.org/10.18632/oncotarget.11098

@article{ccfdebc656b5455485b267217b7dd862,

title = "First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors",

keywords = "RG7356, anti-CD44 humanized antibody, advanced solid tumors, advanced CD44-expressing solid malignancies, phase I trial",

author = "Menke, {C. W.} and Carlos Gomez-Roca and {van Herpen}, Carla and Coveler, {Andrew L.} and Devalingam Mahalingam and Verheul, {Henk M. W.} and {van der Graaf}, {Winette T. A.} and Randolph Christen and Dominik Ruettinger and Stefan Weigand and Cannarile, {Michael A.} and Florian Heil and Michael Brewster and Antje-Christine Walz and Nayak, {Tapan K.} and Ernesto Guarin and Valerie Meresse and {Le Tourneau}, Christophe",

year = "2016",

month = nov,

day = "29",

doi = "10.18632/oncotarget.11098",

language = "English",

volume = "7",

pages = "80046--80058",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "48",

}

Menke, CW, Gomez-Roca, C, van Herpen, C, Coveler, AL, Mahalingam, D, Verheul, HMW, van der Graaf, WTA, Christen, R, Ruettinger, D, Weigand, S, Cannarile, MA, Heil, F, Brewster, M, Walz, A-C, Nayak, TK, Guarin, E, Meresse, V & Le Tourneau, C 2016, 'First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors', Oncotarget, vol. 7, no. 48, pp. 80046-80058. https://doi.org/10.18632/oncotarget.11098

TY - JOUR

T1 - First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

AU - Menke, C. W.

AU - Gomez-Roca, Carlos

AU - van Herpen, Carla

AU - Coveler, Andrew L.

AU - Mahalingam, Devalingam

AU - Verheul, Henk M. W.

AU - van der Graaf, Winette T. A.

AU - Christen, Randolph

AU - Ruettinger, Dominik

AU - Weigand, Stefan

AU - Cannarile, Michael A.

AU - Heil, Florian

AU - Brewster, Michael

AU - Walz, Antje-Christine

AU - Nayak, Tapan K.

AU - Guarin, Ernesto

AU - Meresse, Valerie

AU - Le Tourneau, Christophe

PY - 2016/11/29

Y1 - 2016/11/29

KW - RG7356

KW - anti-CD44 humanized antibody

KW - advanced solid tumors

KW - advanced CD44-expressing solid malignancies

KW - phase I trial

U2 - 10.18632/oncotarget.11098

DO - 10.18632/oncotarget.11098

M3 - Article

C2 - 27507056

VL - 7

SP - 80046

EP - 80058

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 48

ER -